Department of Emergency Medicine, United states.
Department of Neurosurgery, United states.
Am J Emerg Med. 2022 Nov;61:111-116. doi: 10.1016/j.ajem.2022.08.047. Epub 2022 Aug 30.
The nasopharyngeal swab is the gold standard collection method for COVID-19, but is invasive and painful, subsequently resulting in poor patient acceptance. This investigation explores the process of developing and validating an alternative respiratory pathogen collection device that relies on a nasopharyngeal irrigation mechanic. The primary objective was to determine if sufficient pathological sampling can be achieved by mechanism of nasopharyngeal irrigation that is proportionate to the nasopharyngeal swab method.
The study device was designed using Shapr3D modeling software and fabricated on a fused deposition modeling printer. Fifteen participants were enrolled with each receiving a saline nasopharyngeal washing using the study device. Specimen adequacy was evaluated by two real-time reverse transcriptase polymerase chain reaction (PCR) testing methods to identify the presence of the human RNase P gene. Results were evaluated quantitatively through interpretation of the PCR cycle threshold (Ct).
All 15 specimens tested positive for the presence of RNaseP, demonstrating specimen cellularity, adequate extraction of nucleic acids, and the absence of inhibitors to amplification. The mean C value was 29.5 (Applied Biosystems TaqPath RT-qPCR) and 30.7 (NECoV19). All participants felt the study device irrigation procedure was faster than the nasopharyngeal swab, with none experiencing any discomfort from the irrigation mechanism.
The importance of early diagnostic testing and its role in countermeasures for communicable diseases such as COVID-19 is well established in the literature. Innovation to bolster our testing infrastructure is more important now than ever. This study was successful in developing and validating an alternative nasopharyngeal respiratory pathogen collection device that utilizes fluid debridement as its core mechanic. Data from this pilot study demonstrated the study device was successful in producing high-quality specimens for PCR testing. Feedback from the study participants was also in favor of the study device when compared to the nasopharyngeal swab.
鼻咽拭子是 COVID-19 的金标准采集方法,但具有侵入性和痛苦性,因此患者接受度较差。本研究探索了开发和验证替代呼吸道病原体采集装置的过程,该装置依赖于鼻咽冲洗机制。主要目的是确定通过与鼻咽拭子方法成比例的鼻咽冲洗机制是否可以获得足够的病理采样。
使用 Shapr3D 建模软件设计研究装置,并在熔融沉积建模打印机上制造。每个参与者都接受了使用研究装置进行的生理盐水鼻咽冲洗。通过两种实时逆转录聚合酶链反应 (PCR) 测试方法评估标本充分性,以确定人 RNase P 基因的存在。结果通过解释 PCR 循环阈值 (Ct) 进行定量评估。
所有 15 个标本均检测到 RNaseP 的存在,证明了标本的细胞性、核酸的充分提取以及不存在扩增抑制剂。平均 C 值为 29.5(Applied Biosystems TaqPath RT-qPCR)和 30.7(NECoV19)。所有参与者都觉得研究装置冲洗程序比鼻咽拭子快,没有人对冲洗机制感到不适。
早期诊断测试的重要性及其在针对 COVID-19 等传染病的对策中的作用在文献中得到了充分证实。创新以加强我们的测试基础设施现在比以往任何时候都更加重要。本研究成功开发并验证了一种替代的鼻咽呼吸道病原体采集装置,该装置利用液体清创作为其核心机制。这项初步研究的数据表明,该研究装置成功地为 PCR 测试产生了高质量的标本。与鼻咽拭子相比,研究参与者的反馈也支持研究装置。